Bionexus Gene LabBGLC
13F holders, Q4 2024 (December 31)6holders +2
3new positions
1sold out
$0.28avg. 13F price*
At the end of Q4 2024, 6 institutions reported holding Bionexus Gene Lab Corp. (BGLC) in their 13F filings, up 2 from Q3 2024. 3 opened new positions and 1 sold out. The largest holders were UBS Group AG ($31K), XTX Topco Ltd ($9K) and Geode Capital Management, LLC ($7K).
- Company
- Bionexus Gene Lab Corp.
- CUSIP
- 090628207
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $9K |
| Exits | 1 | $6K |
All 13F filers, Q3 2024 → Q4 2024: 60,723 shares bought and 12,960 shares sold, net +47,763 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| UBS Group AG | 0.00% | Add +31.6% | 109,632 | $31K |
| XTX Topco Ltd | 0.00% | New | 32,828 | $9K |
| Geode Capital Management, LLC | 0.00% | No change | 23,681 | $7K |
| Scientech Research LLC | 0.00% | Add +4.0% | 10,796 | $3K |
| JPMorgan Chase & Co. | 0.00% | New | 580 | $162 |
| Morgan Stanley | 0.00% | New | 580 | $162 |
"% of holder's portfolio" is BGLC's weight in each manager's 13F, not the share of Bionexus Gene Lab Corp. the manager owns.